CA2001124C - Treatment of hypertension - Google Patents

Treatment of hypertension Download PDF

Info

Publication number
CA2001124C
CA2001124C CA002001124A CA2001124A CA2001124C CA 2001124 C CA2001124 C CA 2001124C CA 002001124 A CA002001124 A CA 002001124A CA 2001124 A CA2001124 A CA 2001124A CA 2001124 C CA2001124 C CA 2001124C
Authority
CA
Canada
Prior art keywords
potassium salt
potassium
pharmacologically
acceptable
halide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002001124A
Other languages
English (en)
French (fr)
Other versions
CA2001124A1 (en
Inventor
R. Curtis Morris, Jr.
Anthony Sebastian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of CA2001124A1 publication Critical patent/CA2001124A1/en
Application granted granted Critical
Publication of CA2001124C publication Critical patent/CA2001124C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002001124A 1988-10-21 1989-10-20 Treatment of hypertension Expired - Fee Related CA2001124C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26085688A 1988-10-21 1988-10-21
US260,856 1988-10-21

Publications (2)

Publication Number Publication Date
CA2001124A1 CA2001124A1 (en) 1990-04-21
CA2001124C true CA2001124C (en) 2000-01-18

Family

ID=22990921

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002001124A Expired - Fee Related CA2001124C (en) 1988-10-21 1989-10-20 Treatment of hypertension
CA002001123A Expired - Fee Related CA2001123C (en) 1988-10-21 1989-10-20 Treatment of osteoporosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002001123A Expired - Fee Related CA2001123C (en) 1988-10-21 1989-10-20 Treatment of osteoporosis

Country Status (13)

Country Link
US (1) US5804204A (ko)
EP (3) EP0440738B1 (ko)
JP (2) JP2843146B2 (ko)
KR (2) KR0163583B1 (ko)
AT (1) ATE145825T1 (ko)
AU (2) AU634988B2 (ko)
CA (2) CA2001124C (ko)
DE (2) DE68913311T2 (ko)
DK (2) DK175841B1 (ko)
HU (2) HU212106B (ko)
IL (2) IL92076A (ko)
WO (2) WO1990004402A1 (ko)
ZA (2) ZA898018B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674529A (en) * 1995-06-06 1997-10-07 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
AT408416B (de) * 1996-07-19 2001-11-26 Norbert Fuchs Pharmazeutische bzw. diätetische zusammensetzungen
EP1350515A1 (en) * 2002-04-05 2003-10-08 Btg International Limited Low-dose potassium supplementation for the prevention and treatment of hypertension
AU2003219321A1 (en) * 2002-04-05 2003-10-27 Btg International Limited Low-dose potassium supplementation for the prevention and treatment of hypertension
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
US10251909B2 (en) * 2007-02-09 2019-04-09 Board Of Regents, The University Of Texas System Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension
US20090022853A1 (en) * 2007-07-16 2009-01-22 Conopco, Inc., D/B/A Unilever Beverage
US20090196957A1 (en) * 2008-02-06 2009-08-06 Campbell Soup Company Methods and compositions for reducing sodium content in food products
US20110195172A1 (en) * 2008-09-05 2011-08-11 Inge Elisabeth Maria Deutz Beverages comprising potassium
CN114272263A (zh) * 2022-01-10 2022-04-05 伍永田 一种用于治疗高血压疾病的水配方

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
GB1195381A (en) * 1967-04-28 1970-06-17 Arthur H Cox & Company Ltd Pharmaceutical Compositions Comprising Potassium and Chlorine
US3639585A (en) * 1968-03-29 1972-02-01 Res Inst Medicine Chem Method of preventing corticosteroid-induced adverse effects on bon and compositions useful in said method
US3541208A (en) * 1968-09-10 1970-11-17 Arcom Holding Corp Relief of arthritis with a soluble silicate and a soluble polyphosphate
US3921804A (en) * 1974-05-09 1975-11-25 William W Tester Medication dispensing package
SU858830A1 (ru) * 1974-10-23 1981-08-30 Институт медико-биологических проблем Средство дл лечени нарушений ритма сердца
SU946545A1 (ru) * 1978-05-04 1982-07-30 Институт Медико-Биологических Проблем Министерства Здравоохранения Ссср Способ восполнени калиевого дефицита в ткан х
FR2432869A1 (fr) * 1978-08-08 1980-03-07 Armour Montagu Laboratoire Compositions pour le traitement de l'osteoporose associant la calcitonine et le phosphore
US4289750A (en) * 1978-10-16 1981-09-15 Kopp Klaus F Therapy of conditions which may be associated with altered renal function and dosage forms therefor
US4405596A (en) * 1978-10-16 1983-09-20 Helbig Joachim W Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level
US4451454A (en) * 1981-06-16 1984-05-29 Wong Dennis W Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals
US4704269A (en) * 1985-06-11 1987-11-03 Hudson Pharmaceutical Corporation Effervescent antacid and analgesic compositions
JPH0619063B2 (ja) * 1986-04-09 1994-03-16 日本エステル株式会社 粉体塗料用樹脂組成物

Also Published As

Publication number Publication date
JP2843146B2 (ja) 1999-01-06
DE68913311D1 (de) 1994-03-31
HU896567D0 (en) 1991-07-29
HU896889D0 (en) 1991-07-29
DK72691A (da) 1991-04-22
EP0440738B1 (en) 1996-12-04
HU212106B (en) 1996-02-28
IL92076A (en) 1995-08-31
WO1990004402A1 (en) 1990-05-03
JPH04501419A (ja) 1992-03-12
IL92076A0 (en) 1990-07-12
HU208923B (en) 1994-02-28
KR0163583B1 (ko) 1998-12-01
AU634988B2 (en) 1993-03-11
DE68927519D1 (de) 1997-01-16
IL92075A0 (en) 1990-07-12
ATE145825T1 (de) 1996-12-15
CA2001123C (en) 2000-01-18
CA2001124A1 (en) 1990-04-21
WO1990004403A1 (en) 1990-05-03
DE68927519T2 (de) 1997-04-03
DK72791D0 (da) 1991-04-19
DK175840B1 (da) 2005-03-29
AU4622089A (en) 1990-05-14
DK72691D0 (da) 1991-04-19
HUT57989A (en) 1992-01-28
EP0440738A1 (en) 1991-08-14
ZA898017B (en) 1990-12-28
CA2001123A1 (en) 1990-04-21
IL92075A (en) 1995-07-31
HUT63058A (en) 1993-07-28
KR0178033B1 (ko) 1999-03-20
AU635231B2 (en) 1993-03-18
JP2948247B2 (ja) 1999-09-13
DE68913311T2 (de) 1994-05-26
EP0461111B1 (en) 1994-02-23
AU4515489A (en) 1990-05-14
DK175841B1 (da) 2005-03-29
EP0720855A2 (en) 1996-07-10
JPH04501724A (ja) 1992-03-26
KR900701287A (ko) 1990-12-01
EP0720855A3 (en) 1998-07-08
DK72791A (da) 1991-05-14
ZA898018B (en) 1990-12-28
KR900701288A (ko) 1990-12-01
US5804204A (en) 1998-09-08
EP0461111A4 (en) 1991-07-25
EP0440738A4 (en) 1991-08-28
EP0461111A1 (en) 1991-12-18

Similar Documents

Publication Publication Date Title
CA1308659C (en) Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
PUDENZ et al. The role of potassium in familial periodic paralysis
CA2001124C (en) Treatment of hypertension
US5171583A (en) Treatment of osteoporosis using potassium bicarbonate
Jäättelä Clinical efficacy of BS 100-141 in essential hypertension: A single-blind pilot study
US5498428A (en) Treatment of hypertension by oral administration of potassium bicarbonate
US5766640A (en) Simutaneous treatment of osteoporosis and hypertension
JP6027335B2 (ja) 耐糖能異常用飲食品添加剤
Bruun et al. Lithium clearance and renal tubular sodium handling during acute and long-term nifedipine treatment in essential hypertension
CN101663030B (zh) 可用于预防患有胰岛素耐受的前驱糖尿病患者的2型糖尿病及其并发症的组合物
Gifford Jr Essential hypertension: cost-effective evaluation and treatment
AXELROD et al. Insulin resistance
KR20030019444A (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
JP2006523685A (ja) 循環器疾患の治療のためのｌ−カルニチンの使用
Upward et al. Oral labetalol in the management of stable angina pectoris in normotensive patients.
Kuhn Angiotensin-converting enzyme inhibitors
Ko et al. Electrolyte and Metabolic Disorder
Cleghorn Recognition and treatment of Addison's disease
Tablets et al. Pr ACT METFORMIN
JPH04112823A (ja) 痴呆治療剤
Agent Pr RIVA-METFORMIN
MacLennan et al. Disorders of the Heart
Hsia et al. Low-Dose Perindopril and Indapamide Combination Compared with Losartan in the Treatment of Systemic Hypertension: A Randomized, Double-Blind Study

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed